Introducing The Charles River And Quotient Sciences Collaboration

By Eleanor Row, Executive Director of Commercial, Quotient Sciences, and Russell Scammell, Director of Small Molecule Drug Discovery, Charles River

The siloed structure of the pharmaceutical industry often forces drug sponsors to split their development program across multiple service providers, such as contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Dispersing this process among different functional disciplines slows the development timeline, constricts knowledge and material sharing, and is ultimately costly. A holistic approach allows process development, analytical, and formulation development teams to collaborate more efficiently.

Charles River and Quotient Sciences have formed a collaboration which leverages the expertise of both companies to create a world-leading capability that supports customers from discovery through to clinical development. This approach creates an accelerated pathway to advance molecules from early discovery to proof of concept and beyond. Charles River and Quotient Sciences’ capabilities provide deep scientific expertise, flexibility for customers, dedicated project teams, and a bespoke service that is tailored to each development program.

Working in multidisciplinary projects teams enables unique discovery, CMC, clinical, and biopharmaceutics know-how. The integration of discovery and development activities through this collaboration provides optimized decision-making and problem-solving processes as well as efficient tech transfer. Explore how an integrated approach can help bring your product to market faster.